Medetomidine is replacing xylazine in Philly street fentanyl − creating new hurdles for health care providers and drug users
New adulterants are frequently added to the mix. They bring additional and often uncertain risks for people who use drugs, and new challenges for the health care providers and systems who treat them.
The latest adulterant to dominate the supply is medetomidine.
Medetomidine, pronounced meh-deh-TOH-muh-deen, is a drug used in veterinary medicine for sedation, muscle relaxation and pain relief, often during surgery. It is an alpha-2 adrenergic agonist, which essentially means it works by slowing the release of adrenaline in the brain and body.
In May 2024, the Philadelphia Medical Examiner's Office began testing for medetomidine in people who died from fatal overdoses. By the end of the year, 46 of the deceased had tested positive for the substance, in addition to fentanyl and other known chemicals.
In fact, medetomidine is quickly becoming more common in Philadelphia's street opioid supply than even xylazine, a non-FDA-approved sedative linked to skin ulceration, chronic wounds and amputation.
Xylazine was first detected in Philadelphia street drugs in 2006 and became increasingly common starting in 2015. By early 2023, xylazine was detected in 98% of tested dope samples in the city.
However, its presence is steadily dropping, according to local drug-checking program data. The Philadelphia Department of Public Health says medetomidine has emerged as a primary adulterant and is now twice as common as xylazine in drug-checked samples.
Recent studies show even more unusual substances entering the street fentanyl supply, such as the industrial solvent BTMPS.
At the same time, hospital and behavioral health providers are reporting more common presentations of severe withdrawal symptoms among people who use drugs in Philadelphia.
While medetomidine's sedating effects are similar in mechanism to xylazine, it is upward of 10-20 times more potent. It suppresses brain signals in the central nervous system, leading to deep sedation.
Since medetomidine is so powerful and does not act on opioid receptors, a person who overdoses on it often does not respond to the opioid-reversal drug naloxone, which goes by the brand name Narcan, in the manner we commonly expect from people who appear to have overdosed on opioids.
When patients overdose on a combination of opioids and medetomidine, providing naloxone will help individuals start breathing again but does not reverse the sedation caused by the medetomidine.
From our clinical experience, after patients start to breathe normally, providing additional doses of naloxone does not seem to help and even risks prompting opioid withdrawal symptoms.
Additionally, medetomidine presents serious clinical challenges for health care workers treating patients in withdrawal. These patients often experience symptoms such as rapid heart rate, severe spikes in blood pressure, restlessness, disorientation and confusion, and severe vomiting. While many of these symptoms were similar, if less intense, for those withdrawing from opioids and xylazine, the number of patients we are seeing is unprecedented – as is the severity of their symptoms.
While published data on humans' withdrawal from medetomidine is limited, clinicians are drawing comparisons to dexmedetomidine, a related drug used in humans that has shown similar features when withdrawn too quickly.
Researchers and clinicians in Philadelphia's hospitals, including us at Thomas Jefferson University, are analyzing emerging clinical data. This data suggests that existing protocols that effectively controlled withdrawal symptoms in the era when xylazine was common are no longer adequate in the era of medetomidine. New protocols have been developed based on the guidance of local experts and are being tested.
The rise in severe withdrawal symptoms has prompted expanded testing for adulterants such as medetomidine in Jefferson's emergency departments.
Currently, drug testing involves two primary approaches. Qualitative analysis determines the presence or absence of substances. For example, fentanyl and xylazine test strips are commonly used by harm reduction groups and people who use drugs. Unfortunately, they can be unreliable and prone to user error, expiration, misinterpretation and false positives or negatives. This technology is also commonly used in urine drug-testing kits sold over the counter.
Quantitative analysis, on the other hand, is a more sophisticated approach to drug testing. It uses complex technology such as liquid-phase chromatography and mass spectrometry to separate the individual components of a sample and determine their concentration. This form of testing is more expensive and requires specialized equipment and analysts to perform the tests and interpret the results.
Hospitals in the city have begun selectively testing urine and blood samples from patients who present with suspected medetomidine exposure. The labs are looking for the presence of certain drugs and their related byproducts, and also trying to identify distinct concentrations that might be associated with overdose, intoxication and withdrawal.
We believe Philadelphians should be aware of these recent changes in the street drug supply and how people in their communities may react to exposure to medetomidine.
Naloxone is still recommended for a person showing signs of opioid overdose – such as excess sedation, shallow or absent breathing and small pupils. Narcan is freely available at pharmacies around the city. But if the patient starts breathing but does not immediately wake up, additional doses of naloxone should be avoided.
As always, contact 911 for expert assistance and to get patients to an emergency department to complete their care.
Patients who use large amounts of drugs may suffer from severe withdrawal symptoms. Typical medications given to those in opioid withdrawal, such as buprenorphine or methadone, may not be sufficient to treat this constellation of symptoms. Even medications and regimens tailored for xylazine may not be effective.
Patients with severe withdrawal symptoms need to be seen in the emergency department, given the risk of undertreating this emerging condition.
Read more of our stories about Philadelphia.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Kory London, Thomas Jefferson University and Karen Alexander, Thomas Jefferson University
Read more:
Philly hospitals test new strategy for 'tranq dope' withdrawal – and it keeps patients from walking out before their treatment is done
Philly's street fentanyl contains an industrial chemical called BTMPS that's an ingredient in plastic
How opioid deaths tripled in Philly over a decade − and what may be behind a recent downturn
Kory London receives funding from The Sheller Family Foundation.
Karen Alexander receives funding from the National Institutes on Drug Abuse (NIDA).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
3 days ago
- CBS News
Baltimore mass overdose survivor says "chill came though body" after bad batch of drugs
Almost 5,000 people have died from drug overdoses in Baltimore in the past five years alone. Despite a drop in deaths last year, recent mass overdoses in Penn North show there is still a serious problem, and the city council tried to get to a deeper understanding at an oversight hearing Tuesday. Joseph Calloway Jr. told WJZ Investigates he was one of at least 27 people who overdosed at Penn North on July 10. "When I took that hit, it was like a chill came through my body," Calloway said. "My cousin was like, 'Are you alright?' I said, 'I'm cool,' and then in about 15 or 20 minutes, I was gone. I wasn't good to anybody. If you're ready to die, then keep doing what you're doing." Calloway was not ready to die. The overdose scared Calloway so much, he is now in treatment and feels lucky to be alive. He called the overdose, "My start date to being drug free." Calloway said he has had "quite a few wake-up calls" and admitted it is hard to know what is in the illicit drugs being sold in Penn North. "They don't have any heroin on the streets of Baltimore or any streets for that matter," Calloway said. "It's just a bunch of crushed-up pills." Baltimore City has not said what was in the bad batch of drugs at Penn North, but a federal laboratory identified fentanyl and sedatives. Calloway said this experience was far different than any other for him. "I never had a chill go through my body," Calloway said. At an oversight hearing Tuesday, Baltimore City Council members were told Black men are the group most likely to die from drug overdoses in the city. Public Safety Chairman Mark Conway said he has seen two overdoses in front of his own district office along York Road. "One in which I specifically had to find my own dosage of naloxone," Conway said. "Fortunately, that person woke up and was able to get back on his feet before I had to apply it. It just shows the urgency, and the fact that this can really be affecting people anywhere." Conway also noted, "This issue cannot be solved in closed-door rooms. It cannot be solved by really smart people working alone. It takes all of us." In Baltimore City, 777 people died from drug overdoses last year compared to 1,043 in 2023. First responders in Baltimore have used Narcan, the brand name of the drug that reverses overdoses, 635 times through June of this year. The generic name is naloxone. Most overdoses happen in the afternoon, with noon having the most overdose calls. Fentanyl is behind most deadly overdoses, followed by cocaine. Baltimore's Health Department outlined the waves of overdose deaths and responses. Baltimore City Needle Exchange (syringe services program/SSP) (1994), drug take-back programs, opioid prescribing guidelines, Baltimore City Staying Alive program (2004) First responder naloxone access, prescription drug monitoring program (2014), overdose fatality review (2014) Wide naloxone distribution, fentanyl test strips, peer recovery outreach, Baltimore City naloxone standing order (2015) Mobile treatment, harm reduction vending machine, syringe disposal drop boxes, overdose prevention center advocacy, addition of backpacking model for SSP, expansion of SSPs to CBOs, Kids Off Drugs, data dashboards Penn North has seen two mass overdoses in the past month, one week apart. The second mass overdose impacted seven people, sending five of them to hospitals. "I hope that we're just prepared for the next one, and the next one, and the next one. I hope that everyone is out here—and the organizations still show up," said David Carter. "We need resources. We need people to get into housing. We need accurate treatment. Baltimore City got $16 million for housing and $16 million for drug treatment. Where is that money at?" Sam Graves spoke about the open-air drug market at Penn North. "It's open to you, where you can just walk over to who got it—you got this and you got that—and there you go," Graves said.
CNN
3 days ago
- CNN
Former US surgeon general: Opioid fight demands better overdose reversal strategies, stronger policy support
Editor's note: Dr. Jerome Adams, who served as US surgeon general in the first Trump administration, is a distinguished professor in pharmacy practice and public health at Purdue University. The recently passed One Big Beautiful Bill Act, which experts predict will reduce Medicaid coverage for millions of Americans, combined with the proposed elimination of a $56 million grant for overdose reversal training and distribution, threatens to undermine progress in reducing opioid overdose deaths. Medicaid, particularly through its expansion, supports treatment for about 1 million people with opioid use disorder. If federal funding falters, many people could lose access to care, reversing hard-earned gains against overdose deaths that were driven by expanded health care and lifesaving tools. As synthetic opioids like fentanyl fuel a continuing overdose crisis, sustaining progress will demand both robust policy and advancements in overdose reversal strategies. Although drug overdose deaths made a significant drop in 2024 to the lowest level in five years, according to federal estimates, there were still more than 80,000 deaths last year. Synthetic opioids were involved in more than half of those cases. High-potency synthetic opioids (HPSOs) like fentanyl, which is 50 to 100 times more potent than heroin, have reshaped the overdose landscape. Fentanyl can cause rapid respiratory arrest within minutes and often outlasts standard reversal agents. First responders frequently report now having to administer multiple doses of naloxone (best known by the brand name Narcan) to reverse a fentanyl overdose. A recent analysis by Dr. Mark Gold, of the Department of Psychiatry at Washington University, and colleagues explores the challenges of reversing HPSO overdoses, drawing on observational studies, lab data and clinical experience. They emphasize that effective reversal requires matching the agent to the opioid's potency and duration, a complex task given the increasingly unpredictable nature of illicit drugs today. Among the options, nasal nalmefene has emerged as a notable tool due to its rapid onset and longer duration compared with naloxone, the standard reversal drug. Administered via a simple spray, it acts quickly to restore breathing and helps reduce the risk of 'renarcotization,' in which overdose symptoms return after initial reversal. However, the American College of Medical Toxicology and the American Academy of Clinical Toxicology advise caution in adopting nalmefene as a primary agent, citing potential risks like prolonged withdrawal symptoms or the return of respiratory depression as the drug's effects wane. These concerns are not unique to nalmefene, however, as all opioid antagonists carry similar risks. Further, these risks are readily managed with proper medical oversight and monitoring, a standard practice post-reversal. To put it plainly, I'd rather risk having to treat such side effects in a resuscitated and living person than to keep wondering 'what if' about the tens of thousands each year who sadly are not saved with our current efforts. The development of new reversal agents like nalmefene underscores the critical need for sustained research funding to address the evolving opioid crisis. Recent budget proposals, however, include significant cuts to the US National Institutes of Health and the US Centers for Disease Control and Prevention, with the NIH facing a proposed 40% reduction to $27.5 billion and the CDC a 44% cut to $4 billion in 2026, threatening research into new treatments and public health responses. These cuts could stall progress on innovative solutions like Compound 368, which enhances naloxone's potency 7.6-fold and extends its effect tenfold, and covalent naloxone nanoparticles (cNLX-NP), which could sustain therapeutic levels for 48 hours to prevent renarcotization. While promising, cNLX-NP's slower onset requires pairing with fast-acting naloxone for immediate effect. Such potentially life-saving advancements will depend on consistent funding to move from lab to real-world use. Policy has and will continue to play a critical role in stemming the tide. The World Health Organization recommends restricting access to precursor chemicals used in fentanyl production and strengthening international controls on its analogs. I'm glad to see this is one of the few areas in which WHO and the Trump administration agree. Enhanced border security and surveillance can further limit the supply of illicit HPSOs. Equally important is education, with updated training for first responders and bystanders emphasizing the interplay between reversal agents and immediate CPR, as HPSOs rapidly induce hypoxia. Public awareness campaigns should highlight the potency of HPSOs and the need for rapid intervention, newer agents like nalmefene and/ or multiple doses or Narcan, and post-reversal monitoring. Thankfully, the CDC reports a recent decline in national overdose deaths. Yet vulnerabilities persist, particularly in communities facing geographic, racial or demographic disparities. The rise of fentanyl-laced stimulants – which drove a 50-fold increase in related overdose deaths from 2010 to 2021, accounting for 32.3% of fatal overdoses – complicates the crisis. These contaminated drugs turn non-opioid use into a lethal risk, as users often lack opioid tolerance. Comprehensive strategies combining policy, education, and innovative reversal tools are essential to address this polysubstance threat. Protecting Medicaid and overdose prevention funding is critical to sustaining progress in the fight against opioid overdose deaths. By pairing these efforts with evidence-based training and advancements in reversal strategies, we can better equip communities to confront the evolving opioid crisis and save lives.
CBS News
3 days ago
- CBS News
New drug called "flysky" is spreading throughout the Pittsburgh area, authorities say
A new drug called "flysky" has been spreading throughout the Pittsburgh region, and officials are warning that it can be deadly. In Fayette County over the last few days, there have been at least two overdose deaths from the drug. The drug, as it is sometimes labeled on bags sold on the street, is heroin laced with medetomidine, a tranquilizer used in veterinary medicine. Fayette County District Attorney Michael Aubele says that users need to be aware that this drug can be lethal. "My understanding is that medetomidine is a drug that is not affected by Narcan. So if you overdose on medetomidine, Narcan is not going to save you," Aubele said. Aubele says that anyone who may have a bag of flysky can turn it into authorities at several places in the county, including local police stations and the Crime Stoppers office, with no questions asked. He also says that not only are local and state police working to get these drugs off the streets, but that his office will prosecute those who are responsible for delivering these drugs into their community. "We want people to be safe. We want everybody to be alive and to be healthy. You just don't know what you are getting anymore on the street," Aubele added. Not only is this drug popping up in Fayette County and the Pittsburgh area, but it is also being seen in places like Philadelphia and Chicago. For more information on this substance, click here.
